Exploring the Cardiotoxicity Spectrum of Anti-Cancer Treatments: Definition, Classification, and Diagnostic Pathways

作者：Ciro Mauro, Valentina Capone, Rosangela Cocchia, Filippo Cademartiri, Ferdinando Riccardi, Michele Arcopinto, Maie Alshahid, Kashif Anwar, Mariano Carafa, Andreina Carbone, Rossana Castaldo, Salvatore Chianese, Giulia Crisci, Roberta D’Assante, Mariarosaria De Luca, Monica Franzese, Domenico Galzerano, Vincenzo Maffei, Alberto M. Marra, Alfredo Mazza, Brigida Ranieri, Anna D’Agostino, Salvatore Rega, Luigia Romano, Sarah Scagliarini, Chiara Sepe, Olga Vriz, Raffaele Izzo, Antonio Cittadini, Eduardo Bossone, Andrea Salzano · 发表于：Journal of Clinical Medicine · 年份：2023 · DOI：10.3390/jcm12041612 · 被引用次数：11 · 研究领域：Chemotherapy-induced cardiotoxicity and mitigation、Cardiac Imaging and Diagnostics、Acute Myocardial Infarction Research

Early detection and treatment of cancer have led to a noticeable reduction in both mortality and morbidity. However, chemotherapy and radiotherapy could exert cardiovascular (CV) side effects, impacting survival and quality of life, independent of the oncologic prognosis. In this regard, a high clinical index of suspicion is required by the multidisciplinary care team in order to trigger specific laboratory tests (namely natriuretic peptides and high-sensitivity cardiac troponin) and appropriate imaging techniques (transthoracic echocardiography along with cardiac magnetic resonance, cardiac computed tomography, and nuclear testing (if clinically indicated)), leading to timely diagnosis. In the near future, we do expect a more tailored approach to patient care within the respective community along with the widespread implementation of digital health tools.